Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has earned a consensus recommendation of “Buy” from the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $20.78.

INO has been the topic of a number of recent research reports. Aegis restated a “buy” rating and issued a $14.00 price target on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Maxim Group lifted their price objective on shares of Inovio Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, May 24th. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Stifel Nicolaus reiterated a “buy” rating and issued a $11.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, April 25th. Finally, Zacks Investment Research downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, April 17th.

Shares of Inovio Pharmaceuticals (INO) traded up 2.670% during trading on Friday, hitting $5.575. 1,050,511 shares of the company were exchanged. Inovio Pharmaceuticals has a 12 month low of $5.32 and a 12 month high of $9.95. The company’s 50-day moving average price is $7.16 and its 200 day moving average price is $6.84. The stock’s market cap is $416.05 million.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.31). Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The company had revenue of $10.40 million for the quarter, compared to the consensus estimate of $5.83 million. During the same period last year, the firm posted ($0.11) EPS. The company’s revenue for the quarter was up 28.4% on a year-over-year basis. On average, equities analysts predict that Inovio Pharmaceuticals will post ($1.06) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Inovio Pharmaceuticals, Inc. (INO) Receives Consensus Rating of “Buy” from Analysts” was first published by Daily Political and is owned by of Daily Political. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/09/inovio-pharmaceuticals-inc-ino-receives-consensus-rating-of-buy-from-analysts.html.

In other Inovio Pharmaceuticals news, Director David B. Weiner sold 8,000 shares of Inovio Pharmaceuticals stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total value of $64,000.00. Following the completion of the sale, the director now directly owns 740,956 shares in the company, valued at $5,927,648. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.60% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the company. State of Wisconsin Investment Board bought a new position in shares of Inovio Pharmaceuticals during the second quarter worth about $392,000. Schwab Charles Investment Management Inc. raised its position in shares of Inovio Pharmaceuticals by 9.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 334,017 shares of the biopharmaceutical company’s stock worth $2,619,000 after buying an additional 28,173 shares during the period. Candriam Luxembourg S.C.A. bought a new position in shares of Inovio Pharmaceuticals during the second quarter worth about $1,411,000. Private Capital Advisors Inc. bought a new position in shares of Inovio Pharmaceuticals during the second quarter worth about $274,000. Finally, Credit Suisse AG raised its position in shares of Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 69,068 shares during the period. 22.92% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.